Insider Buying: BioDelivery Sciences International Director Acquires 1,800 Shares of Stock (BDSI)
BioDelivery Sciences International (NASDAQ:BDSI) Director Charles Bramlage purchased 1,800 shares of the company’s stock on the open market in a transaction dated Friday, August 22nd. The shares were purchased at an average price of $13.85 per share, for a total transaction of $24,930.00. Following the acquisition, the director now directly owns 1,800 shares in the company, valued at approximately $24,930. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
BDSI has been the subject of a number of recent research reports. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $20.00 in a research note on Friday, August 8th. Separately, analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $21.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $20.50.
BioDelivery Sciences International (NASDAQ:BDSI) opened at 14.66 on Wednesday. BioDelivery Sciences International has a 1-year low of $4.16 and a 1-year high of $14.95. The stock has a 50-day moving average of $13.20 and a 200-day moving average of $10.39. The company’s market cap is $722.7 million.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Friday, August 15th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.07. On average, analysts predict that BioDelivery Sciences International will post $-0.67 earnings per share for the current fiscal year.
BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.